Trial Profile
A retrospective, cohort study to evaluate chronic Myeloid leukemia treatment practices over an extended period and across multiple lines with tyrosine kinase inhibitors Imatinib, dasatinib and nilotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 23 Jan 2017 New trial record
- 04 Jan 2017 Results published in the Pharmacotherapy.